Skip to main navigation
  • FibroGen China
  • Newsroom
  • Contact
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Our Partners
    • ESG
    • Medical Information
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Pancreatic Cancer
    • Prostate Cancer
    • Duchenne Muscular Dystrophy
    • Anemia
    • Publications
  • Pipeline
    • R&D Pipeline
    • Pamrevlumab
    • Roxadustat
    • FG-3246
  • Clinical Trials
    • Our Priorities
    • Pamrevlumab Trials
    • FG-3246 Trials
  • Careers
    • Our Culture
    • Career Opportunities
  • Investors and Media

    Investor Relations

    • Investor Overview
    • Stock Information
    • News Releases
    • Events and Presentations
    • Corporate Governance
    • SEC Filings
    • Financial Information
    • Shareholder Services
    • Investor FAQs
MENU MENU
close x
  • About Us
    • Our Company
    • Our Strategy
    • FibroGen China
    • Executive Team
    • Board of Directors
    • Our Partners
    • ESG
    • Medical Information
    • Contact Us
  • Focus Areas
    • Our Expertise
    • Pancreatic Cancer
    • Prostate Cancer
    • Duchenne Muscular Dystrophy
    • Anemia
    • Publications
  • Pipeline
    • R&D Pipeline
    • Pamrevlumab
    • Roxadustat
    • FG-3246
  • Clinical Trials
    • Our Priorities
    • Roxadustat Trials
    • Pamrevlumab Trials
    • FG-3246 Trials
  • Careers
    • Our Culture
    • Career Opportunities
  • Investors and Media

    Iphone menu

    • Investor Overview
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
      • Contact the Board
    • SEC Filings
    • Financial Information
      • Form 8937
    • Shareholder Services
      • Contact Investor Relations
      • E-mail Alerts
    • Investor FAQs
  • FibroGen China
  • Newsroom
  • Contact

Investors and Media

SEC Filing Details

Document Details

Form
8-K
Filing Date
Apr 4, 2025
Document Date
Apr 2, 2025
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
FibroGen, Inc.
Issuer
FIBROGEN INC

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
XML - XBRL INSTANCE DOCUMENT

Investors and Media

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • SEC Filings
  • Financial Information
  • Shareholder Services
  • Investor FAQs

FibroGen Inc.

Volume:

Minimum 15 minutes delayed. Source: LSEG

Investor and Media Contact

  • Investors:
    David DeLucia, CFA
    Chief Financial Officer
    [email protected]

Shareholder Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts

About Us

  • Our Company
  • Our Strategy
  • FibroGen China
  • Executive Team
  • Board of Directors
  • Our Partners
  • ESG
  • Medical Information
  • Contact Us

Focus Areas

  • Our Expertise
  • Anemia
  • Pancreatic Cancer
  • Duchenne Muscular Dystrophy
  • Publications

Pipeline

  • R&D Pipeline
  • Roxadustat
  • Pamrevlumab

Clinical Trials

  • Our Priorities
  • Roxadustat Trials
  • Pamrevlumab Trials

Careers

  • Our Culture
  • Career Opportunities

Investors & Media

Investor Relations

  • Investor Overview
  • Stock Information
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • SEC Filings
  • Financial Information
  • Shareholder Services
  • Investor FAQs
  • Terms of Use
  • Privacy Notice
  • About Us
  • Focus Area
  • Pipeline
  • Clinical Trials
  • Investors and Media
  • Terms of Use
  • Privacy Notice
  • © 2025 FibroGen, Inc.
  • 350 Bay St, Ste 100 # 6009 San Francisco, CA 94133 USA